Healios K K (PK)【HLOSF】銘柄情報

Healios K K (PK) (HLOSF) 銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

通貨

1.80

( - )

買値

1.35

売値

1.73

出来高

0.00 日の範囲 0.00

1.80 52 週間の範囲 4.45

時価総額

243.003M

前日終値

1.80

始値

時刻

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

US$ 2,084,502

発行済株式数

135,001,900

配当利回り

PER

-7.43

1 株当たり利益 (EPS)

-34.73

歳入

74M

純利益

-3.13B

Healios K.K., together with its subsidiaries, engages in the research, development, manufacturing, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company offers HLCM051, which is preparing for approval for the treatment of acute respiratory d... Healios K.K., together with its subsidiaries, engages in the research, development, manufacturing, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company offers HLCM051, which is preparing for approval for the treatment of acute respiratory distress syndrome; HLCM051, which is preparing for phase 3 clinical trial for the treatment of ischemic stroke; and HLCM051, which is in phase 2 clinical trial for the treatment of trauma, as well as HLCR011, which is in phase 1/2 clinical trial for the treatment of retinal pigmen epithelium and age-related macular degeneration and AKT-01/HLCN061, which is in pre-clinical trial for the treatment of Mesothelioma, Lung cancer, Hepatocellular carcinoma and Gastric cancer(solid tumors). It also develops somatic stem cell and induced pluripotent stem cell regenerative medicines. The company was formerly known as Retina Institute Japan, K.K. and changed its name to Healios K.K. in September 2013. Healios K.K. was incorporated in 2011 and is headquartered in Chiyoda, Japan. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

www.healios.co.jp

本社

Chiyoda, Japan

設立

2026

Healios K K (PK) is listed in the Healthcare sector of the その他OTC with ticker HLOSF. The last closing price for Healios K K (PK) was US$1.80. Over the last year, Healios K K (PK) shares have traded in a share price range of US$ 1.80 to US$ 4.45.

Healios K K (PK) currently has 135,001,900 shares in issue. The market capitalisation of Healios K K (PK) is US$243 million. Healios K K (PK) has a price to earnings ratio (PE ratio) of -7.43.

Halo Resources announces drilling contract awarded and Duport update

Halo Resources announces drilling contract awarded and Duport update VANCOUVER, Jan. 20 /PRNewswire-FirstCall/ -- Marc Cernovitch, Vice...

Halo closes on $6.37 million financing

Halo closes on $6.37 million financing VANCOUVER, Dec. 24 /PRNewswire-FirstCall/ -- Halo Resources Ltd. (TSX.V: HLO, OTC.BB: HLOSF) is pleased...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	-0.5	-21.7391304348	2.3	2.3	1.8	317	1.95789474	CS
26	-0.13	-6.73575129534	1.93	2.75	1.8	214	2.18166667	CS
52	-1.45	-44.6153846154	3.25	4.45	1.8	679	3.68917419	CS
156	0.215	13.5646687697	1.585	4.45	0.9258	1288	2.03872839	CS
260	-12.75	-87.6288659794	14.55	14.55	0.9258	1200	2.03872839	CS

HLOSF - Frequently Asked Questions (FAQ)

What is the current Healios K K (PK) share price?

The current share price of Healios K K (PK) is US$ 1.80

How many Healios K K (PK) shares are in issue?

Healios K K (PK) has 135,001,900 shares in issue

What is the market cap of Healios K K (PK)?

The market capitalisation of Healios K K (PK) is USD 243M

What is the 1 year trading range for Healios K K (PK) share price?

Healios K K (PK) has traded in the range of US$ 1.80 to US$ 4.45 during the past year

What is the PE ratio of Healios K K (PK)?

The price to earnings ratio of Healios K K (PK) is -7.43

What is the cash to sales ratio of Healios K K (PK)?

The cash to sales ratio of Healios K K (PK) is 470.68

What is the registered address of Healios K K (PK)?

The registered address for Healios K K (PK) is Hibiya Mitsui Tower, Chiyoda, Tokyo, 100-0006

What is the Healios K K (PK) website address?

The website address for Healios K K (PK) is www.healios.co.jp

Which industry sector does Healios K K (PK) operate in?

Healios K K (PK) operates in the Biotechnology & Life Sciences sector

Renee 13年前

HLOSF: Plan of Arrangement. Pursuant to the Arrangement, Sendero will issue approximately 20,000,000 Sendero Units to the former shareholders of Halo. Each Halo shareholder will receive Sendero Units in exchange for the Halo shares held on the basis of 0.689553 of a Sendero Unit for each 1 (one) Halo share held. Whenever the exchange results in a fractional Sendero Unit, the number of Sendero Units will be rounded down to the nearest whole Sendero Unit.

http://www.otcbb.com/asp/dailylist_detail.asp?d=07/08/2013&mkt_ctg=NON-OTCBB

👍️0

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Healios K K (PK) (HLOSF)